Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond

Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond

Author: Bernward Garthoff

Publisher: Springer Science & Business Media

ISBN: 9783642793387

Category: Medical

Page: 117

View: 889

Download Now
At the workshop held in Leverkusen on December 1, 1993, Professor Dr. Stanislav Kazda was honored on the occasion of his retirement for his scientific contributions and his involvement in drug development in our company, Bayer AG. In a recent article by Eugene Garfield (Current ContentslLife Sciences 36:3-15, 1993), what most of us participating in this workshop have supposed for years was confirmed: that Kazda is one of the leading scientific authors in academia worldwide. In the said survey of citations of biomedical research articles, Kazda is number 29 in terms of actual impact, individual ~itations, and total number of published manuscripts (and this only covers the time period from 1981 to 1992). In addition, his work has contributed significantly to the number eight ranking of our company in the so-called Corporation List. With the support of colleagues inside and outside the company, Kazda made a new substance class, the 1, 4-dihydropyridines, discovered by Bossert and Vater, well known to the scientific community on a worldwide basis and established its outstanding usefulness in hypertension. He has contributed numerous publi cations on the pharmacology of these calcium antagonists and organized several international conferences on the topic. Although he became famous as a cardiovascular pharmacologist, he started his career as a physician with the subjects obstetrics and gynecology. He studied at the Medical Faculty in Prague and at the Universities of Kasan and Kharkow (1950-1957).
Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond
Language: en
Pages: 117
Authors: Bernward Garthoff, Andreas M. Knorr, Wolf-Dieter Busse, Friedel Seuter
Categories: Medical
Type: BOOK - Published: 2012-12-06 - Publisher: Springer Science & Business Media

At the workshop held in Leverkusen on December 1, 1993, Professor Dr. Stanislav Kazda was honored on the occasion of his retirement for his scientific contributions and his involvement in drug development in our company, Bayer AG. In a recent article by Eugene Garfield (Current ContentslLife Sciences 36:3-15, 1993), what
Dihydropyridines
Language: en
Pages: 119
Authors: Wolf-Dieter Busse, Bernward Garthoff, Friedel Seuter
Categories: Medical
Type: BOOK - Published: 2012-12-06 - Publisher: Springer Science & Business Media

This volume reviews important milestones in the history of the development of 1,4-dihydropyridines starting in the late 1960s. The discovery led to theestablishment of Ca2+ antagonists as leading cardiovascular drugs throughoutthe world. This volume includes presentations of the results of some recent collaborative extramural studies by American investigators.
Environmental Health Perspectives
Language: en
Pages:
Authors: Wolf-Dieter Busse, Bernward Garthoff, Friedel Seuter
Categories: Environmental health
Type: BOOK - Published: 2009-07 - Publisher:

Books about Environmental Health Perspectives
Renewable Raw Materials
Language: en
Pages: 244
Authors: Roland Ulber, Dieter Sell, Thomas Hirth
Categories: Science
Type: BOOK - Published: 2011-04-27 - Publisher: John Wiley & Sons

One of the main challenges facing the chemical industry is the transition to sustainable operations. Industries are taking initiatives to reduce resource intensities or footprints, and by adopting safer materials and processes. Such efforts need to be supported by techniques that can quantify the broad economic and environmental implications of
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents
Language: en
Pages: 298
Authors: J. Morganroth, E. Neil Moore
Categories: Medical
Type: BOOK - Published: 2012-12-06 - Publisher: Springer Science & Business Media

The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for